Stock Research: Ebos

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

Ebos

NZSE:EBO NZEBOE0001S6
22
  • Value
    56
  • Growth
    39
  • Safety
    Safety
    9
  • Combined
    16
  • Sentiment
    52
  • 360° View
    360° View
    22
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

EBOS Group Limited is a marketer, wholesaler, and distributor of healthcare, medical, and pharmaceutical products, and animal care brands. It operates in the Healthcare and Animal Care industries and includes brands such as Symbion, ProPharma, and TerryWhite Chemmart. It operates in Australia and New Zealand. In the last fiscal year, the company had a market cap of $4,833 million, profits of $1,089 million, revenue of $8,793 million, and 5200 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 22 (better than 22% compared with alternatives), overall professional sentiment and financial characteristics for the stock Ebos are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Ebos. The consolidated Sentiment Rank has a good rank of 52, which means that professional investors are more optimistic about the stock than for 52% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 56 or better than 56% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 9, meaning that the share price of Ebos is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 39. ...read more

more
Index
SDG 13
SDG 3
SDG 8
NZSX 50
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Growth
Shows a company's growth potential.
High Growth Tough Times
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
9 11 16 15
Growth
39 43 3 91
Safety
Safety
56 39 55 55
Sentiment
52 65 62 82
360° View
360° View
22 22 12 77
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
37 53 34 49
Opinions Change
50 68 21 50
Pro Holdings
n/a 27 82 60
Market Pulse
82 81 76 85
Sentiment
52 65 62 82
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
9 11 16 15
Growth
39 43 3 91
Safety Safety
56 39 55 55
Combined
16 12 6 49
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
19 17 23 16
Price vs. Earnings (P/E)
58 51 66 61
Price vs. Book (P/B)
12 14 17 23
Dividend Yield
54 40 48 36
Value
9 11 16 15
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
85 49 1 61
Profit Growth
19 20 49 31
Capital Growth
7 22 7 87
Stock Returns
51 71 15 87
Growth
39 43 3 91
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
43 37 48 52
Refinancing
20 10 24 28
Liquidity
73 68 69 62
Safety Safety
56 39 55 55

Similar Stocks

Discover high‑ranked alternatives to Ebos and broaden your portfolio horizons.

Nipro

TSE:8086
Country: Japan
Industry: Health Care Supplies
Size: Large
Full Stock Analysis

Asahi Intecc

TSE:7747
Country: Japan
Industry: Health Care Supplies
Size: Medium
Full Stock Analysis

M3

TSE:2413
Country: Japan
Industry: Health Care Technology
Size: Medium
Full Stock Analysis

Suncorp

ASX:SUN
Country: Australia
Industry: Property & Casualty Insurance
Size: Medium
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.